Can we count your visit with Google Analytics? No ads, no profiles. Details
BIIB
NASDAQAnalystsBuy32+6%Health Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
MS-cashflow run-off race against new-franchise ramp. Tecfidera/Tysabri/Vumerity declining mid-to-high single digits as oral MS competition (Vumerity cannibalization, $NVS Kesimpta, $ROG Ocrevus) compresses pricing. The structural re-rate hinges on Leqembi adoption curve (slow but accelerating post-CMS coverage + subcutaneous AHEAD-3-45 readout) plus Skyclarys ex-US launches and Zurzuvae uptake in PPD.
It reads our $BIIB data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.